Posts Tagged CMC Market Outlook

NDA Outsourcing Up, Despite NME Decline

by

In 2016, outsourced dose form manufacturing of NDA approvals reached 60%, some 10% higher than the five-year average. This and other insights into CMO performance were revealed in PharmSource’s recently published CMO Scorecard. In what proved to be a mediocre year for drug approvals, the increase in outsourcing levels was restricted to the manufacture of […]

Learn more

Bio/Pharmaceutical Outsourcing Report – Special DCAT 2017 Edition

by

PharmSource has published a special DCAT Edition of our proprietary industry briefing, Bio/Pharmaceutical Outsourcing Report. This monthly report reports on and analyzes major developments throughout the CMO industry. It provides expert insight into the significance of industry trends and what they mean for your business. Deepen your understanding of what’s happening in commercial and clinical […]

Learn more

Will Pharma Manufacturing Move Back to the US?

by

Moving global manufacturing operations may be more complicated than it appears. The bio/pharmaceutical industry is still buzzing about President Trump’s meeting with pharmaceutical executives on Jan. 31, 20171. While promising the industry lower taxes and less regulation, the President emphasized that those benefits will come only if the industry lowers drug prices and moves more […]

Learn more

AGC Acquires CMC Biologics

by

AGC Asahi Glass has agreed to acquire biomanufacturer CMC Biologics in a deal valued at ¥60 billion ($500 million). PharmSource estimates that the price represents a multiple of about 3.3x revenues and more than 10x EBITDA. The selling shareholders are three private equity firms: Monitor Clipper Partners; European Equity Partners; and Innoven Partenaires. Closing is […]

Learn more

The Tide Stays High

by

Robust venture capital investment gives CDMOs and CROs a positive outlook for 2017. A year ago, the outlook for contract services was a little uncertain. Equity markets’ appetite for public offerings from emerging bio/pharmaceutical companies had significantly diminished: valuations of emerging bio/pharma companies, as measured by the NASDAQ Biotechnology Index (NBI), had declined by 15% […]

Learn more

Catalent to Acquire Accucaps

by

Catalent has agreed to acquire softgel manufacturer Accucaps Industries Ltd. Financial details of the transaction were not disclosed, but analysts that follow Catalent put the price at $75 million, representing a multiple of 10x EBITDA. The deal is subject to Canadian regulatory approval. Accucaps is owned by Canadian generic pharmaceutical company Apotex, a detail not […]

Learn more

Growing Turkish Pharma Market Attracts Investment Despite Challenges

by

A growing pharmaceutical market, solid infrastructure and ready access to other emerging markets, such as North Africa and the Middle East, as well as Eastern Europe, make Turkey an attractive location for global pharmaceutical companies. But an emphasis on localization, tough pricing regulations, a depreciating currency and a sluggish drug approval system make the market […]

Learn more

Is R&D Productivity Improving?

by

In the past few years, approvals of new drugs have reached levels not seen for decades. The superficial reasons for this are clear: a combination of benign financial market conditions that have enabled companies to raise substantial amounts of cash, and regulatory authorities in Europe and the US that are committed to ensuring that novel […]

Learn more

Five Themes That Will Drive the CMO Industry

by

CMO executives are focusing on M&A activity, new business models, and fundraising limits. Trade shows provide a good opportunity to gauge the temperature of the contract development and manufacturing organization (CDMO) industry and find out which trends and concerns are most on people’s minds. Five themes really stood out from conversations at the CPhI Worldwide […]

Learn more